New drug under watch for rare blood disorder
NCT ID NCT06441578
Summary
This study is monitoring the safety and effectiveness of the drug ADZYNMA in patients with congenital Thrombotic Thrombocytopenic Purpura (cTTP), a rare and serious blood clotting disorder. It will observe about 40 patients in Japan for 18 months to track any side effects and see if the treatment helps control the disease. The study is not testing a new treatment but is watching how the drug performs in real-world medical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.